Clinical Innovations Committee

The Alfred's Clinical Innovations Committee was introduced in 2001-2002 to provide expert advice to the Alfred Health Executive on the principles and framework for introduction of clinical innovation to The Alfred. From 2005 the committee encompasses the whole of Alfred Health.


A Clinical Innovation requiring review by the Clinical Innovation Committee is defined as a clinical practice (therapeutic intervention, diagnostic procedure, new product, model of care or practice change) that is new to Alfred Health Service, that improves patient care, and that:

  • Is not research
  • Is considered by a reasonable body of medical opinion to be significantly different from existing clinical practice
  • Has associated potential risks that are not fully defined,
  • Has credentialing, training or supervisory implications, or
  • Is expected to lead to an adverse financial outcome
  • Is not otherwise reviewed in an alternative Alfred Health Committee.

The introduction of new medicines is the responsibility of the Alfred Health Drug and Therapeutics Committee. Referral to the Clinical Innovations Committee is only required in the event that the drug is associated with an innovative procedure, eg in its administration.

Potential new innovations to Alfred Health are assessed by the Clinical Innovations Committee, chaired by Dr Susannah Ahern, Director Medical Services Development.

The Committee may refer the application subsequently to the Ethics or Medical Appointments Committee in relation to ethical or credentialing issues.

Once an innovation has been approved, a report is required to be provided to the Clinical Innovations Committee, usually after 12 months.